Niagen Bioscience (NASDAQ:NAGE) Shares Up 4.2% – Here’s Why

Niagen Bioscience, Inc. (NASDAQ:NAGE) shot up 4.2% during trading on Tuesday . The company traded as high as $3.53 and last traded at $3.51. 784,621 shares traded hands during mid-day trading, a decline of 13% from the average session volume of 905,632 shares. The stock had previously closed at $3.37.

Analyst Upgrades and Downgrades

A number of research firms recently commented on NAGE. Canaccord Genuity Group dropped their target price on shares of Niagen Bioscience from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Wall Street Zen lowered Niagen Bioscience from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. HC Wainwright cut their target price on Niagen Bioscience from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $10.50.

Niagen Bioscience Price Performance

The firm has a market cap of $273.17 million, a price-to-earnings ratio of 16.33 and a beta of 2.08. The stock’s fifty day moving average price is $4.18 and its 200-day moving average price is $5.22.

Niagen Bioscience (NASDAQ:NAGE) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.01. The firm had revenue of $31.47 million for the quarter. Niagen Bioscience had a net margin of 14.29% and a return on equity of 22.68%. As a group, equities research analysts predict that Niagen Bioscience, Inc. will post 0.22 EPS for the current fiscal year.

Institutional Trading of Niagen Bioscience

Several institutional investors have recently modified their holdings of NAGE. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Niagen Bioscience during the 3rd quarter worth approximately $126,000. Arizona State Retirement System acquired a new stake in shares of Niagen Bioscience during the 3rd quarter valued at about $152,000. AlphaQuest LLC acquired a new stake in shares of Niagen Bioscience during the 3rd quarter valued at about $75,000. Principal Financial Group Inc. acquired a new stake in shares of Niagen Bioscience during the 3rd quarter valued at about $751,000. Finally, Alps Advisors Inc. acquired a new stake in shares of Niagen Bioscience during the 3rd quarter valued at about $443,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.